[FACT study].
Tanaka
Ikuko
I
Department of Laboratory Medicine, Fujita Health University School of Medicine.
Oshima
Hisaji
H
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019386:Alendronate / Q000008:administration & dosage* / Q000009:adverse effects; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D012968:Etidronic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D019317:Evidence-Based Medicine; D005260:Female; D005269:Femur / Q000378:metabolism; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008159:Lumbar Vertebrae / Q000378:metabolism; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D016032:Randomized Controlled Trials as Topic; D000068296:Risedronic Acid
D050071:Bone Density Conservation Agents; D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate